摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

12-methoxy-7-methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[d,g]azacycloundecene | 951388-04-8

中文名称
——
中文别名
——
英文名称
12-methoxy-7-methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[d,g]azacycloundecene
英文别名
17-methoxy-11-methyl-11-azatricyclo[13.4.0.03,8]nonadeca-1(15),3,5,7,16,18-hexaene
12-methoxy-7-methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[d,g]azacycloundecene化学式
CAS
951388-04-8
化学式
C20H25NO
mdl
——
分子量
295.425
InChiKey
CNKNJMJEVKMFAR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    12-methoxy-7-methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[d,g]azacycloundecene氯甲酸乙酯 在 sodium cyanoborohydride 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 4.0h, 生成 ethyl 12-methoxy-5,6,8,9,10,15-hexahydro-7H-dibenzo[d,g]azacycloundecine-7-carboxylate
    参考文献:
    名称:
    Dopamine/Serotonin Receptor Ligands. 16. Expanding Dibenz[d,g]azecines to 11- and 12-Membered Homologues. Interaction with Dopamine D1−D5 Receptors
    摘要:
    Oxygenated 7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecines are potent dopamine receptor antagonists, preferentially at D-1/D-5. We synthesized the hydroxylated, methoxylated, and chlorinated 11-membered and 12-membered homologues of these 10-membered heterocycles. Their affinities for the human cloned D-1-D-5 receptors (radioligand binding) and functionalities (calcium assay) were measured. Enlarging the dibenzazecines to the corresponding dibenzazacycloundecenes and dibenzazacyclododecenes generally maintains the high antagonistic affinity for D-1/D-5 but also leads to a compound with a clozapine-like binding profile due to additional affinity for D-4.
    DOI:
    10.1021/jm070388+
  • 作为产物:
    描述:
    ethyl 12-methoxy-5,6,8,9,10,15-hexahydro-7H-dibenzo[d,g]azacycloundecine-7-carboxylate 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 4.0h, 以73%的产率得到12-methoxy-7-methyl-6,7,8,9,10,15-hexahydro-5H-dibenzo[d,g]azacycloundecene
    参考文献:
    名称:
    Dopamine/Serotonin Receptor Ligands. 16. Expanding Dibenz[d,g]azecines to 11- and 12-Membered Homologues. Interaction with Dopamine D1−D5 Receptors
    摘要:
    Oxygenated 7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecines are potent dopamine receptor antagonists, preferentially at D-1/D-5. We synthesized the hydroxylated, methoxylated, and chlorinated 11-membered and 12-membered homologues of these 10-membered heterocycles. Their affinities for the human cloned D-1-D-5 receptors (radioligand binding) and functionalities (calcium assay) were measured. Enlarging the dibenzazecines to the corresponding dibenzazacycloundecenes and dibenzazacyclododecenes generally maintains the high antagonistic affinity for D-1/D-5 but also leads to a compound with a clozapine-like binding profile due to additional affinity for D-4.
    DOI:
    10.1021/jm070388+
点击查看最新优质反应信息

文献信息

  • Dopamine/Serotonin Receptor Ligands. 16. Expanding Dibenz[<i>d,g</i>]azecines to 11- and 12-Membered Homologues. Interaction with Dopamine D<sub>1</sub>−D<sub>5</sub> Receptors
    作者:Christoph Enzensperger、Franziska K. U. Müller、Bärbel Schmalwasser、Petra Wiecha、Heidi Traber、Jochen Lehmann
    DOI:10.1021/jm070388+
    日期:2007.9.1
    Oxygenated 7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecines are potent dopamine receptor antagonists, preferentially at D-1/D-5. We synthesized the hydroxylated, methoxylated, and chlorinated 11-membered and 12-membered homologues of these 10-membered heterocycles. Their affinities for the human cloned D-1-D-5 receptors (radioligand binding) and functionalities (calcium assay) were measured. Enlarging the dibenzazecines to the corresponding dibenzazacycloundecenes and dibenzazacyclododecenes generally maintains the high antagonistic affinity for D-1/D-5 but also leads to a compound with a clozapine-like binding profile due to additional affinity for D-4.
查看更多